Clinical Report: Monoclonal Antibodies as a Treatment for Diabetic Kidney Disease

Overview

This review evaluates the potential of monoclonal antibodies (mAbs) in treating diabetic kidney disease (DKD), highlighting mechanistic insights and clinical evidence.

Background

Diabetic kidney disease (DKD) affects a significant proportion of diabetes patients and is a leading cause of end-stage renal disease. Current treatments have not fully addressed the residual risk of kidney function decline.

Data Highlights

No numerical data available in the source material.

Key Findings

• Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies did not demonstrate significant renal benefits.
• Anti-CTGF therapy indicated an early signal of reduced albuminuria.
• Anti-suPAR is still under clinical evaluation for its efficacy in DKD.
• Emerging targets like integrin αvβ8 and signal regulatory protein α may enhance kidney-focused modulation.
• PCSK9 monoclonal antibodies, such as evolocumab and alirocumab, may provide renal benefits through lipid lowering.

Clinical Implications

Monoclonal antibodies have potential in DKD treatment, but further research is needed to confirm their efficacy.

Conclusion

Further research is required to optimize the application of monoclonal antibodies in diabetic kidney disease.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. American Diabetes Association, Diabetes Care, 2026 -- Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
6. Nature Reviews Nephrology, 2025 -- Next-generation therapeutics for diabetic kidney disease
7. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
8. Next-generation therapeutics for diabetic kidney disease | Nature Reviews Nephrology